Home » Shop » hot sale » OrenciaDisease-Modifying Antirheumatic Agent Abatacept / Maltose, Preservative Free 250 mg / 15 mL Intravenous Injection Single Use Vial 15 mL Bristol-Myers Squibb00003218710

OrenciaDisease-Modifying Antirheumatic Agent Abatacept / Maltose, Preservative Free 250 mg / 15 mL Intravenous Injection Single Use Vial 15 mL Bristol-Myers Squibb00003218710

Original price was: $881.99.Current price is: $517.57.

Sale!
SKU: 5774797147 Category:

Product Description

Disease-Modifying Antirheumatic Agent
Abatacept / Maltose, Preservative Free
250 mg / 15 mL Intravenous Injection
Single Use Vial 15 mL
Bristol-Myers Squibb00003218710″ title=”Orencia
Disease-Modifying Antirheumatic Agent
Abatacept / Maltose, Preservative Free
250 mg / 15 mL Intravenous Injection
Single Use Vial 15 mL
Bristol-Myers Squibb00003218710″ />Orencia
Disease-Modifying Antirheumatic Agent
Abatacept / Maltose, Preservative Free
250 mg / 15 mL Intravenous Injection
Single Use Vial 15 mL
Bristol-Myers Squibb00003218710

1- REGULATIONS ON PURCHASE OF THESE PRODUCTS VARY FROM STATE TO STATE . IT IS THE PURCHASER’S RESPONSIBILITY TO KNOW AND COMPLY WITH THE LAWS GOVERNING THE DISTRICT IN WHICH THEY LIVE.2-THESE ITEMS WOULD BE USED ONLY BY QUALIFIED CUSTOMERS ( PHYSICIAN OFFICES , DIAGNOSTIC & RESEARCH LABORATORIES , HEALTH CARE PROVIDERS , …. ) WITH VALID PROFESSIONAL LICENSE.3- ANY INQUIRY REGARDING THESE ITEMS WOULD BE PROCESSED AFTER VERIFICATION OF VALID LICENSE TO BE EMAILED AS AN ATTACHMENT TO : [email protected] OR FAXED TO 323-782-0985 )

Manufacturer 00003218710Brand Orencia®Manufacturer Bristol-Myers SquibbApplication Disease-Modifying Antirheumatic AgentContainer Type Single Use VialDosage Form InjectionGeneric Drug Code 26306Generic Drug Name Abatacept / Maltose, Preservative FreeNDC Number 00003-2187-10Storage Requirements Requires RefrigerationStrength 250 mg / 15 mLType IntravenousUNSPSC Code 51201806Volume 15 mLFeatures

ORENCIA® (abatacept) is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA